Aspira Women’s Health Inc. (NYSE:AWH)’s stock price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $6.74 and last traded at $6.74, with a volume of 19206 shares trading hands. The stock had previously closed at $6.34.
Several equities analysts recently commented on AWH shares. William Blair assumed coverage on shares of Aspira Women’s Health in a research report on Thursday, October 29th. They issued an “outperform” rating for the company. Macquarie reissued a “hold” rating on shares of Aspira Women’s Health in a report on Friday, October 30th. Finally, BidaskClub upgraded Aspira Women’s Health from a “hold” rating to a “buy” rating in a research note on Tuesday, December 22nd.
The business has a 50 day simple moving average of $5.18.
Several institutional investors have recently made changes to their positions in AWH. Janney Montgomery Scott LLC raised its stake in Aspira Women’s Health by 38.6% in the third quarter. Janney Montgomery Scott LLC now owns 14,000 shares of the company’s stock valued at $43,000 after buying an additional 3,900 shares in the last quarter. Mercer Global Advisors Inc. ADV purchased a new stake in Aspira Women’s Health during the third quarter worth approximately $31,000. JPMorgan Chase & Co. lifted its stake in Aspira Women’s Health by 86.3% during the third quarter. JPMorgan Chase & Co. now owns 29,547 shares of the company’s stock worth $96,000 after purchasing an additional 13,688 shares during the last quarter. Virtu Financial LLC acquired a new position in Aspira Women’s Health in the third quarter valued at approximately $44,000. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Aspira Women’s Health by 52.1% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 45,354 shares of the company’s stock worth $140,000 after buying an additional 15,531 shares during the last quarter.
Aspira Women’s Health Company Profile (NYSE:AWH)
Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women in the United States. The company provides sells OVA1, Overa, and Ova1PLUS risk of malignancy tests for ovarian cancer.
Featured Article: Dow Jones Industrial Average (DJIA)
Receive News & Ratings for Aspira Women's Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspira Women's Health and related companies with MarketBeat.com's FREE daily email newsletter.